SeekingAlpha · Feb 10, 2026
NYSE · XOMAP
XOMA Corporation
Healthcare · Biotechnology
$24.98
Up+$0.00 (+0.00%)
Updated Aug 27, 2026, 9:29 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 318.48M
- P/E ratio
- 16.64
- Dividend yield
- 8.63%
- 52-week range
- $24.93 – $27.30
- Volume
- 362
- Avg. volume
- 1.08K
Price performance
XOMAP price history
1M range · 0 trading sessions · Daily adjusted prices
XOMAP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest XOMAP news
The latest Smart Investors Daily articles mentioning XOMAP.
Stock researchCompany · Overview
XOMAP research
Overview
Company profile and research snapshot.
Company profile
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 24, 2026 | Leerink Partners | Outperform | — |
| Dec 11, 2025 | Leerink Partners | Outperform | — |
| Dec 11, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Jan 18, 2026
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses
Key Insights Given the large stake in the stock by institutions, XOMA Royalty's stock price might be vulnerable to...
Yahoo · Jan 12, 2026
XOMA Royalty Announces CFO Transition
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. “Tom’s leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator,” stated Owen Hughes, XOMA Royalty’s Chief Executive Officer. “On behalf of the
Yahoo · Dec 30, 2025
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda th
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
